This is one of the most important regulatory questions in the hair care active-ingredient space, and the answer is nuanced. In the United States, the FDA draws a bright line between cosmetics and drugs based on intended use. A shampoo marketed with claims like 'regrowing hair,' 'stimulating new follicle growth,' or 'treating androgenetic alopecia' crosses into drug territory and would require an approved New Drug Application (NDA) — a multi-million dollar regulatory pathway that is not available to private label brands.
What you can say legally in the US under cosmetic claim framing: 'appears to reduce the look of thinning hair,' 'helps hair look fuller and denser,' 'supports a healthy scalp environment for visible hair density,' 'with biotinoyl tripeptide-1, shown in studies to reduce hair fall by X% vs. placebo.' The key is that cosmetic claims describe how something looks or the appearance of hair, not a physiological change to hair follicle biology.
In the EU, the same principle applies under EC No 1223/2009. The EU's list of permitted cosmetic function claims does not include hair regrowth. Claims must be supported by substantiation — if you reference a clinical study on a peptide ingredient, the study conditions (concentration, vehicle, application method) should align with your actual formulation. The EU has a Cosmetic Claims Regulation (EC No 655/2013) with six common criteria: legality, truthfulness, evidential support, honesty, fairness, and informed decision-making.
The safest claim architecture for a peptide hair growth shampoo is to use structure-function cosmetic language backed by the ingredient supplier's published or proprietary study data. Most established peptide ingredient suppliers (e.g., the maker of Capixyl, Anagain, or Redensyl) provide claim support packages that include in-vitro data, clinical study summaries, and pre-cleared claim language that has already been reviewed by regulatory counsel. Use their language as your starting point.
If you want stronger, drug-level claims in the US, the only legal path for a shampoo is to include a recognized OTC drug monograph active — currently only 2% minoxidil or 1% ketoconazole qualify for over-the-counter hair loss claims — and comply with full OTC drug monograph manufacturing requirements (21 CFR Part 211 cGMP, not ISO 22716). This is a fundamentally different product and regulatory track.
Work with a cosmetic regulatory consultant to review all copy before launch. AJ Cosmo Labs connects you with formulators who have experience building defensible claim packages for peptide hair care products, so your brief can include claim guidance from day one.
Read the full guide on Private Label Peptide Hair Growth Shampoo Manufacturer Low MOQ →